KENNEY CHRISTOPHER JOHN 4

4 · Xenon Pharmaceuticals Inc. · Filed Mar 11, 2026

AI-generated summary of this filing

Updated Mar 11, 2026

Xenon (XENE) CMO Christopher Kenney Sells Shares

What Happened

Christopher Kenney, Chief Medical Officer of Xenon Pharmaceuticals (XENE), had 7,500 performance share units (PSUs) vest and convert into common shares on 2026-03-09 (no cash purchase). Following the vesting, he sold 2,771 shares in an open-market transaction on 2026-03-10 at $60.11 per share, generating $166,559. The Form 4 shows the PSU award/conversion entries (7,500 shares) and the subsequent open-market sale.

Key Details

Transaction dates and prices:
- 2026-03-09: 7,500 PSUs vested/converted to 7,500 shares (award/exercise entries at $0.00; derivative conversion).
- 2026-03-10: Open-market sale of 2,771 shares at $60.11 each, proceeds $166,559.
Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
Footnotes:
- F1: PSUs were granted March 11, 2024 and vested upon a board determination; 7,500 shares were earned and vested.
- F2: The 2,771-share sale was made under a pre-established Rule 10b5-1 “sell-to-cover” arrangement (adopted Dec 3, 2025) to satisfy tax withholding related to the PSU vesting.
Filing timeliness: Form filed 2026-03-11 for transactions on Mar 9–10, 2026 — appears to be filed within the normal reporting window (no late-filing flag shown).

Context

These transactions reflect a typical post-vesting settlement and sell-to-cover for tax obligations: PSUs converted into shares, and a portion sold under a prearranged 10b5-1 plan to cover taxes. Such sell-to-cover sales are routine and do not, by themselves, indicate a change in the insider’s overall view of the company.

Form 4

Period: 2026-03-09

Chief Medical Officer

Transactions

Exercise/Conversion
Common Shares
[F1]
2026-03-09+7,500→ 7,500 total
Sale
Common Shares
[F2]
2026-03-10$60.11/sh−2,771$166,559→ 4,729 total
Award
Performance Share Units
[F1]
2026-03-09+7,500→ 7,500 total
→ Common Shares (7,500 underlying)
Exercise/Conversion
Performance Share Units
[F1]
2026-03-09−7,500→ 0 total
→ Common Shares (7,500 underlying)

Footnotes (2)

[F1]Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination.
[F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024.

Signature

/s/ Nathaniel Adams, Attorney-in-fact|2026-03-11

1 file